Myovant Sciences Debt to Equity Ratio 2017-2022 | MYOV
Current and historical debt to equity ratio values for Myovant Sciences (MYOV) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Myovant Sciences debt/equity for the three months ending March 31, 2022 was 0.00.
| Myovant Sciences Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2022-03-31 |
$0.99B |
$-0.47B |
-2.10 |
| 2021-12-31 |
$1.04B |
$-0.43B |
-2.40 |
| 2021-09-30 |
$1.06B |
$-0.38B |
-2.78 |
| 2021-06-30 |
$1.13B |
$-0.40B |
-2.82 |
| 2021-03-31 |
$1.08B |
$-0.35B |
-3.05 |
| 2020-12-31 |
$1.05B |
$-0.27B |
-3.86 |
| 2020-09-30 |
$0.34B |
$-0.20B |
-1.68 |
| 2020-06-30 |
$0.26B |
$-0.14B |
-1.94 |
| 2020-03-31 |
$0.21B |
$-0.11B |
-1.98 |
| 2019-12-31 |
$0.18B |
$-0.05B |
-3.65 |
| 2019-09-30 |
$0.17B |
$0.02B |
9.66 |
| 2019-06-30 |
$0.17B |
$0.08B |
2.15 |
| 2019-03-31 |
$0.17B |
$0.00B |
38.91 |
| 2018-12-31 |
$0.16B |
$0.05B |
3.32 |
| 2018-09-30 |
$0.09B |
$0.07B |
1.27 |
| 2018-06-30 |
$0.09B |
$0.06B |
1.57 |
| 2018-03-31 |
$0.08B |
$0.04B |
2.16 |
| 2017-12-31 |
$0.06B |
$0.08B |
0.68 |
| 2017-09-30 |
$0.02B |
$0.12B |
0.15 |
| 2017-06-30 |
$0.02B |
$0.15B |
0.12 |
| 2017-03-31 |
$0.02B |
$0.17B |
0.11 |
| 2016-12-31 |
$0.01B |
$0.19B |
0.04 |
| 2016-09-30 |
$0.04B |
$-0.04B |
-1.05 |
| 2016-06-30 |
$0.01B |
$-0.01B |
-1.06 |
| 2016-03-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.236B |
$0.231B |
|
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
|
